ADPGK and neoplasm: In neoantigen vaccine studies, PD-1 ICB improved MC38 tumor control elicited by nanoparticle complexes of CpG and neoantigens, including the MC38 neoantigens Adpgk and Copg1 and mutant KRAS neoantigens.